139 related articles for article (PubMed ID: 19701249)
1. Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT.
Oshima K; Sato M; Terasako K; Kimura S; Okuda S; Kako S; Kanda Y
Bone Marrow Transplant; 2010 Apr; 45(4):781-2. PubMed ID: 19701249
[No Abstract] [Full Text] [Related]
2. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation.
Wingard JR; Nash RA; Przepiorka D; Klein JL; Weisdorf DJ; Fay JW; Zhu J; Maher RM; Fitzsimmons WE; Ratanatharathorn V
Biol Blood Marrow Transplant; 1998; 4(3):157-63. PubMed ID: 9923414
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.
Jacobson P; Uberti J; Davis W; Ratanatharathorn V
Bone Marrow Transplant; 1998 Aug; 22(3):217-25. PubMed ID: 9720734
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?
Chapman JR; Nankivell BJ
Nephrol Dial Transplant; 2006 Aug; 21(8):2060-3. PubMed ID: 16728428
[No Abstract] [Full Text] [Related]
5. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus in hematopoietic stem cell transplantation.
Fortune K; Couriel D
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):835-41. PubMed ID: 19545215
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of calcineurin inhibitor-induced pain syndrome after allo-SCT.
Kakihana K; Ohashi K; Murata Y; Tsubokura M; Kobayashi T; Yamashita T; Sakamaki H; Akiyama H
Bone Marrow Transplant; 2012 Apr; 47(4):593-5. PubMed ID: 21625227
[No Abstract] [Full Text] [Related]
9. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.
Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2003 Oct; 32(8):777-84. PubMed ID: 14520421
[TBL] [Abstract][Full Text] [Related]
10. [Graft-versus-host disease: friend or foe?].
Kanda Y
Rinsho Ketsueki; 2008 Aug; 49(8):583-91. PubMed ID: 18800606
[No Abstract] [Full Text] [Related]
11. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR
Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
[TBL] [Abstract][Full Text] [Related]
13. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
14. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
Oshima K; Kanda Y; Nakasone H; Arai S; Nishimoto N; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Mar; 83(3):226-32. PubMed ID: 17918253
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus clearance is age-dependent within the pediatric population.
Przepiorka D; Blamble D; Hilsenbeck S; Danielson M; Krance R; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(6):601-5. PubMed ID: 11041564
[TBL] [Abstract][Full Text] [Related]
16. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
Bleyzac N
Fundam Clin Pharmacol; 2008 Dec; 22(6):605-8. PubMed ID: 19049662
[TBL] [Abstract][Full Text] [Related]
17. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients.
Jin M; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Bone Marrow Transplant; 2008 Oct; 42(7):455-9. PubMed ID: 18622423
[TBL] [Abstract][Full Text] [Related]
18. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases.
Miyakoshi S; Kusumi E; Matsumura T; Hori A; Murashige N; Hamaki T; Yuji K; Uchida N; Masuoka K; Wake A; Kanda Y; Kami M; Tanaka Y; Taniguchi S
Biol Blood Marrow Transplant; 2007 Jul; 13(7):771-7. PubMed ID: 17580255
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of a slow-release tacrolimus for a patient with tacrolimus-induced renal injury after hemopoietic stem cell transplantation].
Hosonuma R; Fujiwara S; Sasazaki M; Hirata Y; Yamamoto C; Uesawa M; Oh I; Matsuyama T; Mori M; Ozawa K; Muroi K
Rinsho Ketsueki; 2012 Apr; 53(4):469-71. PubMed ID: 22687983
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.
Furlong T; Kiem HP; Appelbaum FR; Carpenter PA; Deeg HJ; Doney K; Flowers ME; Mielcarek M; Nash RA; Storb R; Martin PJ
Biol Blood Marrow Transplant; 2008 May; 14(5):531-7. PubMed ID: 18410895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
